These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Anti-atherosclerotic and plasma lipid lowering effects of the novel calcium blocker with alpha 1-adrenoceptor antagonistic activity, monatepil, in high cholesterol diet-fed Japanese Macaca fuscata monkeys. Miyazaki M; Hosoki K; Okunishi H; Ishii K; Ikeno A; Okazaki Y Arzneimittelforschung; 1994 Mar; 44(3):288-97. PubMed ID: 8192692 [TBL] [Abstract][Full Text] [Related]
6. [Calcium antagonists and development of the atheromatous plaque]. Weber S Arch Mal Coeur Vaiss; 1997 May; 90 Spec No 2():51-3. PubMed ID: 9295927 [TBL] [Abstract][Full Text] [Related]
7. Calcium antagonists in experimental atherosclerosis. Use-dependence of isradipine: a potential explanation for enhanced action in atherosclerotic animals and tissue selectivity. Hof RP; Rüegg UT Am J Hypertens; 1991 Feb; 4(2 Pt 2):107S-113S. PubMed ID: 1826999 [TBL] [Abstract][Full Text] [Related]
8. [Modification of coronary arteriosclerosis in man by calcium antagonists?]. Schneider W; Roebruck P; Cieslinski G; Noack H; Kober G; Alle M; Kaltenbach M Z Kardiol; 1991; 80 Suppl 9():63-71. PubMed ID: 1796651 [TBL] [Abstract][Full Text] [Related]
9. [Effects of calcium antagonists on atherosclerosis progression and intima media thickness]. Zannad F Drugs; 2000; 59 Spec No 2():39-46. PubMed ID: 11002857 [TBL] [Abstract][Full Text] [Related]
12. Hemodynamic, antivasoconstrictor, and antiatherosclerotic effects of calcium antagonists in animal models of atherosclerosis. Hof RP; Tapparelli C; Weinstein DB J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S7-12. PubMed ID: 1695307 [TBL] [Abstract][Full Text] [Related]
13. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Herbette LG; Vecchiarelli M; Sartani A; Leonardi A Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437 [TBL] [Abstract][Full Text] [Related]
15. Differential effect of two calcium channel blockers--nifedipine and diltiazem--on atherogenesis in hypercholesterolemic hamster. Raicu M; Pojoga L; Simionescu N; Simionescu M J Submicrosc Cytol Pathol; 1996 Apr; 28(2):265-75. PubMed ID: 8964051 [TBL] [Abstract][Full Text] [Related]
16. Antiatherogenic properties of calcium antagonists. Bond MG; Purvis C; Mercuri M J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S87-92; discussion S92-3. PubMed ID: 1726013 [TBL] [Abstract][Full Text] [Related]
17. The effect of ACE inhibitors on atheroma formation is potentiated by association with a calcium channel blocker. A biochemical and ultrastructural study. Raicu M; Pojoga L; Simionescu N; Simionescu M J Submicrosc Cytol Pathol; 1997 Jul; 29(3):317-28. PubMed ID: 9267040 [TBL] [Abstract][Full Text] [Related]
18. Interventions that beneficially influence the evolution of coronary atherosclerosis. The case for calcium channel blockers. Waters D; Lespérance J Circulation; 1992 Dec; 86(6 Suppl):III111-6. PubMed ID: 1424044 [TBL] [Abstract][Full Text] [Related]
19. Role of calcium antagonists in progression of arteriosclerosis. Evidence from animal experiments and clinical experience. Part I. Preventive effects of calcium antagonists in animal experiments. Frey M; Just H Basic Res Cardiol; 1994; 89 Suppl 1():161-76. PubMed ID: 7945170 [TBL] [Abstract][Full Text] [Related]
20. Endothelium, atherosclerosis and calcium channel blockers. Biswas TK J Indian Med Assoc; 2003 Jul; 101(7):428-31. PubMed ID: 14748381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]